A trusted physician audience and efficient digital distribution support attractive margins. Q1 FY27 revenue grew 7% to $156.6 million, while adjusted EBITDA declined and AI-related investment increased. The key question is whether new clinical tools strengthen engagement and profitable monetization enough to justify their cost. Rapid query growth is not a substitute for a sustainable revenue model.

What the Market May Be Mispricing

Debate	Research judgment
Physician engagement and advertiser ROI	A trusted physician audience and efficient digital distribution support attractive margins.
Clinical AI monetization and trust	Physician engagement, advertiser returns, campaign renewals, large-customer expansion and product costs drive value.
Economic margins after AI costs and SBC	Q1 adjusted EBITDA margin was 47.7%, down from 54.7%, while GAAP net margin declined more sharply.

Doximity operates a professional network and workflow tools for U.S. medical professionals. It monetizes pharmaceutical and health-system marketing, hiring and related services, while communication and clinical tools support engagement. Doximity Ask adds an AI clinical-information offering. The economic link is indirect: useful physician engagement attracts paying customers, but not every free interaction generates incremental revenue.

Business Takeaway

Doximity operates a professional network and workflow tools for U.S. Physician engagement, advertiser returns, campaign renewals, large-customer expansion and product costs drive value.

Physician marketing and digital workflow remain valuable categories, but pharmaceutical budgets, privacy rules and AI competition influence growth. The size of healthcare spending is not Doximity's directly monetizable TAM. Clinical usefulness and trusted distribution matter more than broad AI-market estimates.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
WebMD — Medscape	Direct: physician attention and pharmaceutical marketing	Product scope; no matched operating-scale series	Competes for HCP marketing budgets	Customer choice in the stated segment only
OpenEvidence (private)	Direct segment: clinical AI attention and HCP marketing	Product scope; no matched operating-scale series	Competes for physician engagement	Customer choice in the stated segment only
Sermo (private)	Segment-specific: physician community and research engagement	Product scope; no matched operating-scale series	Competes for physician attention	Customer choice in the stated segment only
Microsoft Teams; Zoom	Substitute segment: health-system communications	Product scope; no matched operating-scale series	Competes only in relevant workflow budgets	Customer choice in the stated segment only

Industry Takeaway

Clinical usefulness and trusted distribution matter more than broad AI-market estimates. The base case requires evidence of profitable adoption within that market.

Competitive Landscape

Physician marketing, recruiting and clinical workflow are distinct revenue pools. Docusign and Zeta are excluded as weak general software/marketing analogies.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
WebMD — Medscape	No consistent comparable series	Direct: physician attention and pharmaceutical marketing	Established clinical content and advertiser relationships	Doximity combines a professional network with workflow tools	Competes for HCP marketing budgets
OpenEvidence (private)	No consistent comparable series	Direct segment: clinical AI attention and HCP marketing	Purpose-built clinical information interface	Not a full substitute for hiring and communications products	Competes for physician engagement
Sermo (private)	No consistent comparable series	Segment-specific: physician community and research engagement	Professional community and paid-research participation	Different workflow and monetization mix	Competes for physician attention
Microsoft Teams; Zoom	No consistent comparable series	Substitute segment: health-system communications	Enterprise communications distribution	Not equivalent to Doximity's physician network and marketing inventory	Competes only in relevant workflow budgets

Moat Assessment

Verified physician reach, professional trust and workflow integration form a strong niche advantage. Competing information services and clinical AI tools can capture attention. Maintaining accuracy, trust and privacy is essential to preserving the moat.

Moat direction: Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Verified physician reach, professional trust and workflow integration form a strong niche advantage. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2027. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2025	570.4	19.98%	90.20%	40.46%	273.27	47.91%	72.39	201	915.66	12.4
FY2026	644.86	13.05%	89.09%	34.40%	326.46	50.62%	121.63	199	748.6	10.19
Q1 FY2027	$156.618	N/D	84.9%	21.5%	$41.925 (derived: CFO - capex)	26.8%	$36.752	191.169	$273.604	N/D
Q2 FY2027	$174.537	N/D	85.5%	25.2%	$93.285 (derived: current YTD - prior YTD)	53.4%	$40.565 (derived: current YTD - prior YTD)	187.804	$218.614	N/D
H1 FY2027	$331.155	N/D	85.2%	23.4%	$135.21 (derived: CFO - capex)	40.8%	$77.317	189.475	$218.614	N/D

Financial Takeaways

Q1 adjusted EBITDA margin was 47.7%, down from 54.7%, while GAAP net margin declined more sharply. TTM FCF of $306 million included SBC of $137 million. The valuation uses economic EPS after compensation and AI investment, rather than applying a premium multiple to unadjusted FCF.

Financial direction: Deteriorating — assess the reported trend alongside dilution and the balance sheet.

Current Valuation

Metric	Value
Price Snapshot	$32.60 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	$5.94B
Enterprise Value	$5.27B
Trailing P/E	39.58
Provider forward P/E	23.40
EV / Sales	8.03

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	EV / Sales	Growth / Margin / Risk Context
DOCS — Doximity, Inc.	Subject company	Public	23.40	8.03	physician network and workflow software; 3Y revenue-growth estimate 6.73%; operating margin 30.57%
Sermo; clinical AI assistants	Direct operating competitor / substitute	Unquoted / mixed operators	N/A	N/A	physician community, information and attention; no compatible standalone public multiple used
WebMD — Medscape	Direct: physician attention and pharmaceutical marketing	Private	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes for HCP marketing budgets
OpenEvidence (private)	Direct segment: clinical AI attention and HCP marketing	Private	N/A — private	N/A — private	Competes for physician engagement
Microsoft Teams; Zoom	Substitute segment: health-system communications	Operating product / listed parent	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes only in relevant workflow budgets

Comparable takeaway: Physician marketing, recruiting and clinical workflow are distinct revenue pools. Docusign and Zeta are excluded as weak general software/marketing analogies. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 26×, versus the provider's current forward P/E of 23.4×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of $25.95, versus the central base FV of $28.83. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	3Y revenue CAGR 2%; sustainable 2029 EPS $0.80 after compensation; 18× P/E; 13% discount rate; Marketing pressure and AI costs limit 2029 economic EPS to $0.80.	$9.98	25%	Execution, financing or competitive setbacks remain credible	-69.4%
Base	3Y revenue CAGR 10%; sustainable 2029 EPS $1.60 after compensation; 26× P/E; 13% discount rate; Stable customer monetization produces $1.60 of 2029 economic EPS.	$28.83	50%	Most likely operating trajectory, requiring measurable progress	-11.6%
Bull	3Y revenue CAGR 18%; sustainable 2029 EPS $2.50 after compensation; 32× P/E; 13% discount rate; Strong AI-supported engagement and paid adoption produce $2.50 of 2029 economic EPS.	$55.44	25%	Successful product conversion and operating leverage; not assured	+70.1%
Probability-Weighted	Sum of each scenario value × its probability	$30.77	100%	Judgmental scenario probabilities	-5.6%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
• Cross-check methods: Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in the valuation workpaper.
• Key valuation dependencies: Physician engagement and advertiser ROI; Clinical AI monetization and trust; Economic margins after AI costs and SBC. All forward figures are independent research assumptions, not company guidance or consensus.
• Valuation confidence / Risk Level: 58/100 / Medium-High. Scenario values are sensitive to sustainable earnings and terminal multiples.
• Margin-of-safety conclusion: Hold / Watch at $33.35. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

Management has built a profitable platform and is investing to protect relevance. Capital allocation should demonstrate that clinical AI deepens the franchise at attractive returns. Monitor paid monetization, retention and compensation intensity alongside engagement metrics.

Management Takeaway

Monitor paid monetization, retention and compensation intensity alongside engagement metrics.

Analyzed call: Q1 FY2027, complete material Q&A · Research snapshot: 2026-10-21

The table consolidates related questions and follow-ups from each material participant in the complete call.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Brian Peterson / Raymond James	What evidence supports the clinical AI opportunity, and how mature is monetization?	Management described encouraging evidence but said the monetization ramp remains early.	Value the opportunity only as permissions and evidence mature.
Craig Hettenbach / Morgan Stanley	Does AI search generate enough revenue to cover its serving cost?	Management said search revenue exceeds serving cost.	Confirm that this opportunity converts into profitable recurring demand.
Michael Cherny / Leerink Partners	How does the broader AI strategy reach enterprise customers?	Management said existing enterprise relationships support distribution.	Confirm that this opportunity converts into profitable recurring demand.
Ryan Daniels / Blair	What is driving sales demand for the new offerings?	Management said new buying categories are generating customer requests.	Confirm that this opportunity converts into profitable recurring demand.
Ryan MacDonald / Needham & Company	How do health-system requirements and privacy affect the offering?	Management said enterprise security remains a source of differentiation.	Confirm that this opportunity converts into profitable recurring demand.
Elizabeth Anderson / Evercore ISI	How much of pharmaceutical budgets is currently allocated to AI?	Management said AI spending remains a small share of those budgets.	Confirm that this opportunity converts into profitable recurring demand.
Steven Valiquette / Mizuho Securities	Has the outlook for the healthcare marketing recovery changed?	Management said its broad market assumptions are unchanged.	Treat the stated timetable as conditional on demonstrated execution.
Jessica Tassan / Piper Sandler	How does the buyer mix for AI products expand the opportunity?	Management said clinical content broadens the opportunity.	Stress monetization if competition or mix reduces economic yield.
Sean Dodge / BMO Capital Markets	How do agency relationships help reach pharmaceutical customers?	Management said agency partnerships improve reach.	Confirm that this opportunity converts into profitable recurring demand.
Alexei Gogolev / JPMorgan	Can customers buy search together with core marketing campaigns?	Management said search and core campaigns can be packaged together.	Confirm that this opportunity converts into profitable recurring demand.
Scott Schoenhaus / KeyBanc	How is the purchasing cadence for new AI offerings developing?	Management said future purchasing formats are still evolving.	Confirm that this opportunity converts into profitable recurring demand.

Analyst-Q&A Takeaway

AI engagement creates new monetization options, but product revenue is early and marketing-market growth remains modest. Search economics need to offset investment costs without relying on a rapid budget shift.

Source	Type	Date / Period	What It Supports
Doximity - Doximity Announces Fiscal 2027 First Quarter Financial Results	Company IR / earnings filing	Q1 FY2027	Latest operating results, guidance, products and financial supplement
DOCS complete earnings-call transcript	Transcript	Q1 FY2027	Prepared remarks and all material Q&A exchanges
DOCS regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
DOCS valuation statistics	Market data	2026-10-20 close; ratios retrieved 2026-10-21	Market capitalization, shares, quoted multiples and current ratios
DOCS historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
DOCS historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
DOCS historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Zeta Global Holdings Corp. statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
FY2026 10-K — member, marketing and workflow competition	Regulatory filing / primary product evidence	FY ended 2026-03-31; checked 2026-10-28	Medscape, OpenEvidence and communications competitors by budget
Sermo — community and medical research offering	Regulatory filing / primary product evidence	Current product description; checked 2026-10-28	Physician-community overlap; distinct research economics
SEC XBRL company facts — DOCS	Regulatory filing (as tagged)	FY2027, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics

Research context

• Company: Doximity, Inc.

• Ticker: DOCS

• Exchange: NYSE

• Sector / Industry: Health Care / physician network and workflow software

• Template version: 2.7

• Research date: 2026-10-21

• Valuation / score price snapshot: $32.60 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: On the Radar

• Owned: No

• Primary operating period reviewed: Q1 FY2027

• Historical period reviewed: TTM, FY 2026, FY 2025; latest balance-sheet date shown below

• Latest investor presentation reviewed: Results release and associated financial tables; no separate slide deck materially used

• Latest earnings call reviewed: Q1 FY2027, complete material Q&A

• Latest post-earnings management commentary reviewed: No separate later management presentation incorporated

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

DOCS — Doximity, Inc.

Company & Research Metadata

• Company: Doximity, Inc.

• Ticker: DOCS

• Exchange: NYSE

• Sector / Industry: Health Care / physician network and workflow software

• Template version: 2.7

• Research date: 2026-10-21

• Valuation / score price snapshot: $32.60 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: On the Radar

• Owned: No

• Primary operating period reviewed: Q1 FY2027

• Historical period reviewed: TTM, FY 2026, FY 2025; latest balance-sheet date shown below

• Latest investor presentation reviewed: Results release and associated financial tables; no separate slide deck materially used

• Latest earnings call reviewed: Q1 FY2027, complete material Q&A

• Latest post-earnings management commentary reviewed: No separate later management presentation incorporated

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

What's Changed Since Previous Review

Current Review: 2026-10-28

Previous Review: 2026-10-21

Update Trigger: Competitor relevance and analyst-Q&A correction

Area	Previous View	Current View	Investment Impact
Competition	Preceding operating and comparable-company classifications	Product/customer/geographic boundaries corrected; direct rivals separated from substitutes, partners and valuation anchors	Corrects the competitive comparison; does not by itself re-underwrite the valuation
Analyst questions	Prior source-linked Q&A summaries	Complete questions and sentence-form management answers; all 11 existing rows retained	Improves readability while preserving the recorded exchange meaning
Valuation and scores	Approved operating/price snapshots, scenarios, scores and decisions	Preserved	No price refresh, rerank or change to valuation assumptions in this correction pass

Thesis: No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

Investment Snapshot

Metric	Current View
Price Snapshot	$32.60 — 2026-11-03 regular-session close, America/New_York
Rating / Zone Status	Hold / Watch
Bear / Base / Bull Fair Value	$9.98 / $28.83 / $55.44
Scenario Probabilities	25% / 50% / 25%
Probability-Weighted Fair Value	$30.77
Probability-Weighted Expected Return	-5.6%
Bear-Case Return	-69.4%
Strong Buy Zone	≤ $10.98
Buy Zone	>$10.98–$24.62
Avoid Chasing Above	> $34.19
Quality Score / Tier	81.3 / Tier A
Opportunity Score / Rank	46.7 / #50 of 76
Risk Level	Medium-High
Tracking / Ownership	On the Radar / Not Owned

Decision rationale: DOCS is Hold / Watch at $33.35, with -7.7% probability-weighted upside and -70.1% bear-case return. A trusted physician audience and efficient digital distribution support attractive margins. Confidence is 58/100 because the earnings conversion, competitive and capital assumptions below remain conditional.

Investment Thesis

A trusted physician audience and efficient digital distribution support attractive margins. Q1 FY27 revenue grew 7% to $156.6 million, while adjusted EBITDA declined and AI-related investment increased. The key question is whether new clinical tools strengthen engagement and profitable monetization enough to justify their cost. Rapid query growth is not a substitute for a sustainable revenue model.

What the Market May Be Mispricing

Debate	Research judgment
Physician engagement and advertiser ROI	A trusted physician audience and efficient digital distribution support attractive margins.
Clinical AI monetization and trust	Physician engagement, advertiser returns, campaign renewals, large-customer expansion and product costs drive value.
Economic margins after AI costs and SBC	Q1 adjusted EBITDA margin was 47.7%, down from 54.7%, while GAAP net margin declined more sharply.

Business Overview

Doximity operates a professional network and workflow tools for U.S. medical professionals. It monetizes pharmaceutical and health-system marketing, hiring and related services, while communication and clinical tools support engagement. Doximity Ask adds an AI clinical-information offering. The economic link is indirect: useful physician engagement attracts paying customers, but not every free interaction generates incremental revenue.

Business Takeaway

Doximity operates a professional network and workflow tools for U.S. Physician engagement, advertiser returns, campaign renewals, large-customer expansion and product costs drive value.

Industry, TAM & Market Share

Physician marketing and digital workflow remain valuable categories, but pharmaceutical budgets, privacy rules and AI competition influence growth. The size of healthcare spending is not Doximity's directly monetizable TAM. Clinical usefulness and trusted distribution matter more than broad AI-market estimates.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
WebMD — Medscape	Direct: physician attention and pharmaceutical marketing	Product scope; no matched operating-scale series	Competes for HCP marketing budgets	Customer choice in the stated segment only
OpenEvidence (private)	Direct segment: clinical AI attention and HCP marketing	Product scope; no matched operating-scale series	Competes for physician engagement	Customer choice in the stated segment only
Sermo (private)	Segment-specific: physician community and research engagement	Product scope; no matched operating-scale series	Competes for physician attention	Customer choice in the stated segment only
Microsoft Teams; Zoom	Substitute segment: health-system communications	Product scope; no matched operating-scale series	Competes only in relevant workflow budgets	Customer choice in the stated segment only

Industry Takeaway

Clinical usefulness and trusted distribution matter more than broad AI-market estimates. The base case requires evidence of profitable adoption within that market.

Customer Economics

Physician engagement, advertiser returns, campaign renewals, large-customer expansion and product costs drive value. Free workflow tools can lower audience acquisition costs, but AI inference and development spending must be recovered through monetization or retention. Hiring demand is cyclical.

Customer-Economics Takeaway

The economic test is Economic margins after AI costs and SBC. Hiring demand is cyclical.

Competitive Landscape & Moat

Competitive Landscape

Physician marketing, recruiting and clinical workflow are distinct revenue pools. Docusign and Zeta are excluded as weak general software/marketing analogies.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
WebMD — Medscape	No consistent comparable series	Direct: physician attention and pharmaceutical marketing	Established clinical content and advertiser relationships	Doximity combines a professional network with workflow tools	Competes for HCP marketing budgets
OpenEvidence (private)	No consistent comparable series	Direct segment: clinical AI attention and HCP marketing	Purpose-built clinical information interface	Not a full substitute for hiring and communications products	Competes for physician engagement
Sermo (private)	No consistent comparable series	Segment-specific: physician community and research engagement	Professional community and paid-research participation	Different workflow and monetization mix	Competes for physician attention
Microsoft Teams; Zoom	No consistent comparable series	Substitute segment: health-system communications	Enterprise communications distribution	Not equivalent to Doximity's physician network and marketing inventory	Competes only in relevant workflow budgets

Moat Assessment

Verified physician reach, professional trust and workflow integration form a strong niche advantage. Competing information services and clinical AI tools can capture attention. Maintaining accuracy, trust and privacy is essential to preserving the moat.

Moat direction: Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Verified physician reach, professional trust and workflow integration form a strong niche advantage. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Financial Profile

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2027. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2025	570.4	19.98%	90.20%	40.46%	273.27	47.91%	72.39	201	915.66	12.4
FY2026	644.86	13.05%	89.09%	34.40%	326.46	50.62%	121.63	199	748.6	10.19
Q1 FY2027	$156.618	N/D	84.9%	21.5%	$41.925 (derived: CFO - capex)	26.8%	$36.752	191.169	$273.604	N/D
Q2 FY2027	$174.537	N/D	85.5%	25.2%	$93.285 (derived: current YTD - prior YTD)	53.4%	$40.565 (derived: current YTD - prior YTD)	187.804	$218.614	N/D
H1 FY2027	$331.155	N/D	85.2%	23.4%	$135.21 (derived: CFO - capex)	40.8%	$77.317	189.475	$218.614	N/D

Financial Takeaways

Q1 adjusted EBITDA margin was 47.7%, down from 54.7%, while GAAP net margin declined more sharply. TTM FCF of $306 million included SBC of $137 million. The valuation uses economic EPS after compensation and AI investment, rather than applying a premium multiple to unadjusted FCF.

Financial direction: Deteriorating — assess the reported trend alongside dilution and the balance sheet.

Management & Capital Allocation

Management has built a profitable platform and is investing to protect relevance. Capital allocation should demonstrate that clinical AI deepens the franchise at attractive returns. Monitor paid monetization, retention and compensation intensity alongside engagement metrics.

Management Takeaway

Monitor paid monetization, retention and compensation intensity alongside engagement metrics.

Valuation

Current Valuation

Metric	Value
Price Snapshot	$32.60 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	$5.94B
Enterprise Value	$5.27B
Trailing P/E	39.58
Provider forward P/E	23.40
EV / Sales	8.03

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	EV / Sales	Growth / Margin / Risk Context
DOCS — Doximity, Inc.	Subject company	Public	23.40	8.03	physician network and workflow software; 3Y revenue-growth estimate 6.73%; operating margin 30.57%
Sermo; clinical AI assistants	Direct operating competitor / substitute	Unquoted / mixed operators	N/A	N/A	physician community, information and attention; no compatible standalone public multiple used
WebMD — Medscape	Direct: physician attention and pharmaceutical marketing	Private	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes for HCP marketing budgets
OpenEvidence (private)	Direct segment: clinical AI attention and HCP marketing	Private	N/A — private	N/A — private	Competes for physician engagement
Microsoft Teams; Zoom	Substitute segment: health-system communications	Operating product / listed parent	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes only in relevant workflow budgets

Comparable takeaway: Physician marketing, recruiting and clinical workflow are distinct revenue pools. Docusign and Zeta are excluded as weak general software/marketing analogies. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 26×, versus the provider's current forward P/E of 23.4×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of $25.95, versus the central base FV of $28.83. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	3Y revenue CAGR 2%; sustainable 2029 EPS $0.80 after compensation; 18× P/E; 13% discount rate; Marketing pressure and AI costs limit 2029 economic EPS to $0.80.	$9.98	25%	Execution, financing or competitive setbacks remain credible	-69.4%
Base	3Y revenue CAGR 10%; sustainable 2029 EPS $1.60 after compensation; 26× P/E; 13% discount rate; Stable customer monetization produces $1.60 of 2029 economic EPS.	$28.83	50%	Most likely operating trajectory, requiring measurable progress	-11.6%
Bull	3Y revenue CAGR 18%; sustainable 2029 EPS $2.50 after compensation; 32× P/E; 13% discount rate; Strong AI-supported engagement and paid adoption produce $2.50 of 2029 economic EPS.	$55.44	25%	Successful product conversion and operating leverage; not assured	+70.1%
Probability-Weighted	Sum of each scenario value × its probability	$30.77	100%	Judgmental scenario probabilities	-5.6%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
• Cross-check methods: Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in the valuation workpaper.
• Key valuation dependencies: Physician engagement and advertiser ROI; Clinical AI monetization and trust; Economic margins after AI costs and SBC. All forward figures are independent research assumptions, not company guidance or consensus.
• Valuation confidence / Risk Level: 58/100 / Medium-High. Scenario values are sensitive to sustainable earnings and terminal multiples.
• Margin-of-safety conclusion: Hold / Watch at $33.35. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

Analyst Questions

The table consolidates related questions and follow-ups from each material participant in the complete call.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Brian Peterson / Raymond James	What evidence supports the clinical AI opportunity, and how mature is monetization?	Management described encouraging evidence but said the monetization ramp remains early.	Value the opportunity only as permissions and evidence mature.
Craig Hettenbach / Morgan Stanley	Does AI search generate enough revenue to cover its serving cost?	Management said search revenue exceeds serving cost.	Confirm that this opportunity converts into profitable recurring demand.
Michael Cherny / Leerink Partners	How does the broader AI strategy reach enterprise customers?	Management said existing enterprise relationships support distribution.	Confirm that this opportunity converts into profitable recurring demand.
Ryan Daniels / Blair	What is driving sales demand for the new offerings?	Management said new buying categories are generating customer requests.	Confirm that this opportunity converts into profitable recurring demand.
Ryan MacDonald / Needham & Company	How do health-system requirements and privacy affect the offering?	Management said enterprise security remains a source of differentiation.	Confirm that this opportunity converts into profitable recurring demand.
Elizabeth Anderson / Evercore ISI	How much of pharmaceutical budgets is currently allocated to AI?	Management said AI spending remains a small share of those budgets.	Confirm that this opportunity converts into profitable recurring demand.
Steven Valiquette / Mizuho Securities	Has the outlook for the healthcare marketing recovery changed?	Management said its broad market assumptions are unchanged.	Treat the stated timetable as conditional on demonstrated execution.
Jessica Tassan / Piper Sandler	How does the buyer mix for AI products expand the opportunity?	Management said clinical content broadens the opportunity.	Stress monetization if competition or mix reduces economic yield.
Sean Dodge / BMO Capital Markets	How do agency relationships help reach pharmaceutical customers?	Management said agency partnerships improve reach.	Confirm that this opportunity converts into profitable recurring demand.
Alexei Gogolev / JPMorgan	Can customers buy search together with core marketing campaigns?	Management said search and core campaigns can be packaged together.	Confirm that this opportunity converts into profitable recurring demand.
Scott Schoenhaus / KeyBanc	How is the purchasing cadence for new AI offerings developing?	Management said future purchasing formats are still evolving.	Confirm that this opportunity converts into profitable recurring demand.

Analyst-Q&A Takeaway

AI engagement creates new monetization options, but product revenue is early and marketing-market growth remains modest. Search economics need to offset investment costs without relying on a rapid budget shift.

Thesis Monitoring

Driver	Current State	Positive Trigger / Catalyst	Negative Trigger / Falsifier	What It Changes
Physician engagement and advertiser ROI	A trusted physician audience and efficient digital distribution support attractive margins.	Revenue trajectory sustains approximately 10% annual growth on a comparable basis	Growth remains below the 2% bear assumption over a full operating cycle	Revenue outlook and scenario probabilities
Clinical AI monetization and trust	Physician engagement, advertiser returns, campaign renewals, large-customer expansion and product costs drive value.	After-cost earnings progress toward the base implied net margin of 32.2%	Competition, credit losses or service costs make that margin trajectory unattainable	Margins, moat score and valuation multiple
Economic margins after AI costs and SBC	Q1 adjusted EBITDA margin was 47.7%, down from 54.7%, while GAAP net margin declined more sharply.	Financing and compensation remain consistent with 175.6M economic shares in the 2029 base case	Required capital or cumulative dilution materially exceeds the model without matching earnings	Financial score, confidence and downside value

Quality & Opportunity Scorecards

Quality Score

Component	Score	Weight	Weighted Contribution	Evidence
Business durability and economics	84	25%	21.0	Physician engagement, advertiser returns, campaign renewals, large-customer expansion and product costs drive value.
Moat and competitive position	85	25%	21.3	Verified physician reach, professional trust and workflow integration form a strong niche advantage.
Growth runway and durability	76	20%	15.2	Physician marketing and digital workflow remain valuable categories, but pharmaceutical budgets, privacy rules and AI competition influence growth.
Financial quality and balance sheet	83	15%	12.5	Q1 adjusted EBITDA margin was 47.7%, down from 54.7%, while GAAP net margin declined more sharply.
Management, governance and capital allocation	76	15%	11.4	Management has built a profitable platform and is investing to protect relevance.
Quality Score	81.3	100%	81.3	Weighted score, independent of ownership and current price

• Quality Tier: A
• Speculative override: None

Opportunity Score

Component	Raw Input	Normalized Score	Weight	Weighted Contribution
Quality	81.3	81.3	30%	24.4
Probability-weighted upside	-5.6%	38.8	35%	13.6
Bear-case downside	-69.4%	0.0	20%	0.0
Risk / valuation confidence	58	58.0	15%	8.7
Opportunity Score		46.7	100%	46.7

• Opportunity Rank: #50 of 76
• Zone Status: Hold / Watch

Portfolio Context

• Tracking tier: On the Radar
• Owned: No
• Tracking source of truth: ontheradar.md
• Portfolio source of truth: portfolio/holdings.md
• Scoring independence: Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

Investment Decision History

Timestamp	Price	Rating	Zone Status	Buy Zone	Strong Buy Zone	Avoid Chasing Above	Base FV	P/W FV	P/W Return	Quality	Opportunity / Rank	Change / Rationale
2026-10-21 (America/New_York)	$33.35	Hold / Watch	Hold / Watch	>$10.98–$24.62	≤ $10.98	> $34.19	$28.83	$30.77	-7.7%	81.3	45.2 / #43	Initial missing-file analysis; common-universe ranking; independent scenario assumptions

---

Material Sources

Source	Type	Date / Period	What It Supports
Doximity - Doximity Announces Fiscal 2027 First Quarter Financial Results	Company IR / earnings filing	Q1 FY2027	Latest operating results, guidance, products and financial supplement
DOCS complete earnings-call transcript	Transcript	Q1 FY2027	Prepared remarks and all material Q&A exchanges
DOCS regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
DOCS valuation statistics	Market data	2026-10-20 close; ratios retrieved 2026-10-21	Market capitalization, shares, quoted multiples and current ratios
DOCS historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
DOCS historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
DOCS historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Zeta Global Holdings Corp. statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
FY2026 10-K — member, marketing and workflow competition	Regulatory filing / primary product evidence	FY ended 2026-03-31; checked 2026-10-28	Medscape, OpenEvidence and communications competitors by budget
Sermo — community and medical research offering	Regulatory filing / primary product evidence	Current product description; checked 2026-10-28	Physician-community overlap; distinct research economics
SEC XBRL company facts — DOCS	Regulatory filing (as tagged)	FY2027, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics